Resources

Antibiotics player Summit Therapeutics is gearing up for a new clinical trial of its lead asset, an antibiotic for Clostridium difficile infection, thanks to an $8.8 million cash infusion from the U.S. Biomedical Advanced Research and Development Authority. That...

In this week's EuroBiotech Report, Roche's risdiplam clears another phase 3 SMA trial, Merck KGaA spinout raises cash and Korean VCs back PDC*line.

In our EuroBiotech roundup this week, a liver disease biotech raises €11 million, Autolus offers stock and Abivax plans midphase trial. 

Merck KGaA spinout iOnctura has raised a €15 million ($17 million) series A round to support an early-phase solid tumor trial. The company is gearing up to generate data on PI3Kδ inhibitor IOA-244 in humans while hustling a second candidate through...

Germany-based digital medical technology company Brainlab has acquired VisionTree Software for an undisclosed amount. Based in San Diego, US, VisionTree Software is associated with the development of cloud-based and patient-centric data collection and health...

US-based Argon Medical Devices has commercially launched two inferior vena cava (IVC) filter retrieval kits in the US. The newly launched products, Single-Loop and Triple-Loop retrieval kits have secured approval from the US Food and Drug Administration (FDA) and are...

Roche’s risdiplam has come through another late-phase test, triggering improvements in the motor skills of infants with type 1 spinal muscular atrophy. The clinical success comes months before the FDA is set to decide whether to approve the survival motor...

As the medical industry continues its quest for accurate and reliable diagnostic tools, more is becoming understood about the science of the sniff. The olfactory system of mammals is a powerful bio-sensor, its complex network of receptors capable of receiving and...

Medtronic has revealed three-month results from a multicentre randomised controlled trial (RCT) comparing differential target multiplexed (DTM) spinal cord stimulation (SCS) therapy using its Intellis platform with conventional SCS therapy. Intellis platform is...

Hernia repair is one of the world’s most common surgical procedures. A hernia occurs when body organs or fatty tissues protrude out of any wall or opening of the surrounding muscles. The most common site of hernia occurrence is the groin. Hernias are visible as...

2019 was an exciting and busy year at Atlas Venture. Take a look at our year filled with new joiners, partnerships, financings, R&D progress, and more. View the newsletter. The post Atlas Venture’s 2019 Year in Review appeared first on Atlas Venture.

America’s healthcare system is transitioning, albeit slowly, from a volume based payment system, to a focus on paying for value.  As part of this, last October, the Office of Inspector General (OIG) of the Department of Health and Human Services (HHS)...

When we started to think about changing our company name, we knew it wasn’t something to take lightly — changing our brand and outward facing image was a big deal!  Several companies rebranded over the last few years and built successful biotech...

It’s that time of year again when we pause to reflect on the state of the industry – and there’s more to focus on in biopharma today than just the drug pricing debate. As I described last year, we host two major events in the 4Q every year:...

The perennial drug pricing debate has reached a fever pitch, as loud as it’s ever been over the past few decades. Politicians on both sides are bashing the drug industry with the typical talking points about exorbitant prices, countered of course by the expected...

AMDR’s Fall 2019 Newsletter The post Fall 2019 Newsletter appeared first on AMDR.

IFM Therapeutics has raised $55.5 million to launch its third drug subsidiary as well as an incubator, both of which are focused on developing new therapies for inflammatory diseases and cancers. Read more. The post IFM Lands $55.5M to Launch NewCo Quattro...

Word of the “triple win” from reprocessing single use medical devices has reached New Zealand! AMDR works on global harmonization of regulatory laws to bring reprocessing to more hospitals worldwide. “Any single one of its benefits would have enough...

Today Alkermes announced its acquisition of Rodin Therapeutics, a leader in the field of synaptic dysfunction and neuronal epigenetics. Read more. The post Thinking Boldly: Alkermes Acquires Rodin Therapeutics appeared first on Atlas Venture.

Neuroscience has had a tough run of news lately. With Amgen deprioritizing neuro this year, Pfizer doing the same last year, and others like BMS, GSK, and AZ cutting back on CNS a few years earlier, it would seem dark times for neuroscience R&D. Add...

Brian MacDonald’s original foray into treating iron dysregulation by injecting hepcidin, a small peptide hormone key for iron homeostasis, didn’t quite get off the ground. This time, the former GSK executive is taking a fresh approach — by regulating...